Want to see SE:BIOSGN full AI Analyst Report?
BIOSGN Stock Chart & Stats
kr42.60
<kr0.01(1.20%)
At close: 4:00 PM EST
kr42.60
<kr0.01(1.20%)
Day’s Range― - ―
52-Week Rangekr0.47 - kr7.30
Previous CloseN/A
Volume13.64K
Average Volume (3M)126.26K
Market Cap
kr231.77M
Enterprise Valuekr77.44
Total Cash (Recent Filing)kr15.37M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.38
Shares Outstanding82,188,120
10 Day Avg. Volume207,862
30 Day Avg. Volume126,261
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.89
Price to Sales (P/S)0.00
P/FCF Ratio-2.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.1
Revenue Forecast (FY)kr1.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of reported debt limits interest and refinancing obligations, preserving flexibility for research spending or future fundraising. This provides a relative financial advantage even though the company remains dependent on external capital.
Focused Antifungal DevelopmentA focused therapeutic strategy can concentrate limited resources, scientific expertise, and development decisions on a defined unmet-need area. This may support clearer execution than a broadly diversified early-stage biotech portfolio.
Modified Amphotericin B PlatformBuilding BSG005 on a modified version of an established antifungal compound gives the program a defined scientific foundation. If development succeeds, the modification could support differentiation while retaining relevance to invasive fungal infections.
Bears Say
No Recurring Commercial RevenueThe lack of recurring product revenue means Biosergen cannot currently fund operations through commercial sales. Continued development therefore depends on financing, partnerships, or eventual approval, increasing execution and capital dependence.
Widening Net LossesThe sharp increase in net losses indicates rising cost intensity without corresponding revenue or operating leverage. Persistent losses could accelerate capital needs and reduce the resources available to advance the clinical pipeline.
Accelerating Cash DepletionA materially larger cash burn raises the risk that additional funding will be required before the company generates operating revenue. Declining equity and assets further reduce the balance-sheet cushion available to absorb ongoing R&D spending.
Biosergen AB News
BIOSGN FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was kr0.47 and its highest was kr7.30 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is kr231.77M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Nov 18, 2026 which is in 89 days.
How were Biosergen AB’s earnings last quarter?
Currently, no data Available
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 82,188,120 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in SE:BIOSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.
Technical Analysis
BioInvent International AB
―
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―